Date: 2016-04-04
Type of information: Nomination
Compound:
Company: AOP Orphan Pharmaceuticals (Austria)
Therapeutic area: Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 4, 2016, AOP Orphan announced that Roland Bindeus has been appointed new Head of the Hematology & Oncology Business Unit. Dr Roland Bindeus (38)is a biochemist that was most recently the general manager of Baxalta Austria, and brings with him ten years of scientific and market experience in the field of rare diseases. He started his career in the pharmaceutical industry in 2005 at Amgen, where he was particularly involved in the management of clinical studies. In 2008, he moved to Baxter and concentrated on rare diseases in immunological and hematological indications, firstly in the Global Medical Affairs division. He then went on to face the business challenges in this specialized area as Product Manager and Sales & Marketing Manager, further developing close ties to major national and international opinion leaders. Last year, he was given overall responsibility for the Baxalta immunology business in Austria and Switzerland and subsequently for managing the Austrian sales organization so as to develop the local market and organization structure. At AOP Orphan, he will realign the Hematology & Oncology Business Unit, as well as strategically prepare and promote upcoming product launches.
Financial terms:
Latest news:
